Avalo Therapeutics Inc — Cash Flow (NASDAQ:AVTX) | MetaTrader

Open full chart

Financials

Overview Rapor Statistics Dividends

Quarterly Annual

Cash from operating activities -40.54 M-70.89 M-26.75 M-30.68 M-49.06 M -52.26 M Cash from investing activities 11.13 M-113 K-95 K-133 K356 K -84.12 M Cash from financing activities 44.78 M106.76 M-14.7 M25.04 M175.85 M 81.61 M Free cash flow -40.6 M-71 M-26.85 M-30.84 M-49.06 M -52.26 M

Haberler

BTIG’ye Göre Bu Yılın En İyi Sağlık Hisseleri

Top Healthcare Stocks for This Year According to BTIG

Avalo Therapeutics Stock Has More Than 200% Upside? Analyst Breaks Down Bull And Bear Case - Avalo Therapeutics (NASDAQ:AVTX)

Guggenheim, Avalo Therapeutics’i Alım tavsiyesi ile takibe aldı, hisse yükseldi

Avalo Therapeutics stock rises after Guggenheim initiates with Buy rating

Guggenheim initiates Avalo Therapeutics stock with Buy rating on IL-1β therapy

Avalo Therapeutics hissesi, deneme verileri öncesinde H.C. Wainwright’ın Al tavsiyesini koruyor

Avalo Therapeutics stock maintains Buy rating at H.C. Wainwright ahead of trial data

This Valvoline Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Avalo Therapeutics (NASDAQ:AVTX), Lexeo Therapeutics (NASDAQ:LXEO)

Mizuho, Avalo Therapeutics hissesini HS ilacı potansiyeli nedeniyle Üstün Performans tavsiyesiyle başlattı

Mizuho initiates Avalo Therapeutics stock with Outperform rating on HS drug potential

Avalo Therapeutics expands leadership with two senior appointments